An in-depth analysis of original antigenic sin in dengue virus infection
about
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsFeasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplexRecent advances in understanding dengueThe Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseRandomized controlled ferret study to assess the direct impact of 2008-09 trivalent inactivated influenza vaccine on A(H1N1)pdm09 disease riskStructural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-ReactivityThe structural basis for serotype-specific neutralization of dengue virus by a human antibodyVaccines and immunization strategies for dengue preventionAssessing the potential of a candidate dengue vaccine with mathematical modelingA Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in PatientsHumoral cross-reactivity between Zika and dengue viruses: implications for protection and pathologyLow levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.Current progress in dengue vaccinesSubversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice.The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection.In Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers.Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells.Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries.Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus.Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, MexicoTherapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.Detection of serotype-specific antibodies to the four dengue viruses using an immune complex binding (ICB) ELISAClinical outcome and genetic differences within a monophyletic Dengue virus type 2 populationQuantifying the emergence of dengue in Hanoi, Vietnam: 1998-2009.The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.The role of pre-existing cross-reactive antibodies in determining the efficacy of vaccination in humans: study protocol for a randomized controlled trialB-cell responses during primary and secondary dengue virus infections in humans.Functionality of dengue virus specific memory T cell responses in individuals who were hospitalized or who had mild or subclinical dengue infectionHigh-resolution analysis of intrahost genetic diversity in dengue virus serotype 1 infection identifies mixed infections.Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity.B-Cell Responses to Human Bocaviruses 1-4: New Insights from a Childhood Follow-Up StudyDominant cross-reactive B cell response during secondary acute dengue virus infection in humansModelling Virus and Antibody Dynamics during Dengue Virus Infection Suggests a Role for Antibody in Virus Clearance.Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity.Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearanceAssociation between magnitude of the virus-specific plasmablast response and disease severity in dengue patientsLower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.
P2860
Q24289014-55342118-0881-4858-AC55-3AA33B0FF190Q24737461-A48F1882-7705-423F-8D7C-751C09A81652Q26766156-A3F0F7ED-810E-41CA-9313-90CDD8FDF365Q26995782-21B07434-03B5-4E3A-8256-598B5604BFDAQ27330166-D13C9605-86B8-44F6-A3A0-11B082F93167Q27678419-FC2CA423-D18F-4563-BBBB-EB3C17A71C02Q27681306-280AEF0C-A891-4038-AC29-09D33579D07EQ28077521-33368616-C56A-40FD-99D3-3C0D30BC5304Q28730914-5DD2E2A2-2C55-4593-AA7D-F5D420940936Q28954730-159A2590-874A-4983-B046-629957F1C388Q29994510-249ABF8B-AC2A-4993-8727-CDDECACDB820Q30392050-8E5447FF-A555-4005-82AE-D7D43D5A9B71Q33408300-B66F1354-C3FC-47BF-91B8-BBBA190CFA12Q33414560-946F1EC8-FFC7-44BB-BDAF-D391DC210D76Q33817714-ECA10AC3-E491-4067-BB45-3F740DFFC255Q33867337-03976646-7509-458C-BF51-314D3EDCFE0DQ34184747-881B741E-2064-4364-BFF7-BC93C25F49A9Q34226542-67FEDCF5-FCE6-4D51-B5BD-FFA7991BB396Q34354665-83479AA8-70DC-48E7-866C-8C78BDDFCC44Q34408025-CD9878E1-CDCF-4506-AF6B-781B6E561818Q34496118-D3DA2612-DAF9-43DC-A67E-C018AA0B5A42Q34607919-BF85C290-2EAA-470D-BDCF-0E012A9413E5Q34779065-742E2EEF-6268-4C78-B6A1-30CC78FC8D46Q35081258-373B5BD7-3998-42A4-A6DB-0FE613388396Q35220195-8ECD56D5-5FD7-4743-AF0F-664894C28508Q35235314-143567DA-D489-435D-AC9A-FE83442AD06BQ35236379-6805B0E2-3856-43FD-B2B2-E0ADB62335E0Q35496004-A10CFB9B-B6D4-4AF1-A1EF-C4FD7C0747E6Q35567408-316CF31B-896C-470C-A481-570D312CC34CQ35601805-3DE0C371-2111-4485-8933-BFEBFAF7F22EQ35665847-FE5D12C6-9158-4B86-A430-B0A6489124CEQ35669397-84739FA0-8321-4178-ABB3-9763E2D7547EQ35791624-DAB3AD0D-3328-4C24-B0CF-400112D92D3FQ35842365-09354E52-9AFC-4FE5-A33B-584D3DCAF2B1Q36026321-78512508-D1E1-4894-A846-15ACECFB305EQ36172100-8C4E6E10-4F61-475F-B3F5-19F7AEB86E1FQ36286276-F3C92370-BE8B-46F9-A6C1-10D3BBCE69BFQ36363799-0179CCD5-1C50-4E09-B0D6-3A96E1B9EFFDQ36487320-77A34338-D464-457B-8A92-B55CC9760793Q36616521-8C3831DA-B419-4DDC-93A2-4FAD48F4ED02
P2860
An in-depth analysis of original antigenic sin in dengue virus infection
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An in-depth analysis of original antigenic sin in dengue virus infection
@ast
An in-depth analysis of original antigenic sin in dengue virus infection
@en
An in-depth analysis of original antigenic sin in dengue virus infection
@nl
type
label
An in-depth analysis of original antigenic sin in dengue virus infection
@ast
An in-depth analysis of original antigenic sin in dengue virus infection
@en
An in-depth analysis of original antigenic sin in dengue virus infection
@nl
prefLabel
An in-depth analysis of original antigenic sin in dengue virus infection
@ast
An in-depth analysis of original antigenic sin in dengue virus infection
@en
An in-depth analysis of original antigenic sin in dengue virus infection
@nl
P2093
P2860
P50
P3181
P356
P1433
P1476
An in-depth analysis of original antigenic sin in dengue virus infection
@en
P2093
Aleksandra Flanagan
Alison E Cowper
Claire M Midgley
Emily Waiyaiya
Hai Bac Tran
Jonathan M Grimes
Martha Bajwa-Joseph
Pojchong Chotiyarnwon
Pojchong Chotiyarnwong
Prida Malasit
P2860
P304
P3181
P356
10.1128/JVI.01826-10
P407
P5008
P577
2011-01-01T00:00:00Z